Department of Biochemistry

From left are Bonnie Miller, MD, VUMC; Odell Kumeh, MD, MPH, ULCHS; Marie Martin, PhD, MEd, VUMC; Bernice Dahn, MD, MPH, ULCHS; Kristina Talbert-Slagle, PhD, Yale; and Comfort Enders, MEd, ULCHS.
February 24, 2022

Capacity building activities and new curriculum strengthen medical education in Liberia

Liberia’s fragile health system is being strengthened through U.S.-Liberia partnerships focused on medical education and capacity building at the country’s only medical school, A.M. Dogliotti (AMD) School of Medicine in the College of Health Sciences at the University of Liberia.

By Kristin Centers
February 10, 2022

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).

By John Howser
December 9, 2021

Former chair of Biochemistry Michael Waterman has died

Michael Waterman, PhD, former chair of the Department of Biochemistry for 18 years, died Nov. 7

By VUMC News and Communications
November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
September 30, 2021

Molecular imaging of C. diff infection

C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.

By Leigh MacMillan
The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
By Leigh MacMillan
July 29, 2021

Cortez named chair of Department of Biochemistry

David Cortez, PhD, Richard N. Armstrong, PhD, Professor of Innovation in Biochemistry and professor of Biochemistry, has been appointed chair of the Department of Biochemistry.
By Wendy Bindeman
July 22, 2021

Researchers discover that protein switches functions to regulate DNA replication

Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.
By Leigh MacMillan
April 15, 2021

Arrhythmia culprit: supertrafficking ion channel

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.
By Leigh MacMillan
February 4, 2021

Gene network for leukemia factor

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.
By Leigh MacMillan
December 8, 2020

Cortez named interim chair of the Department of Biochemistry; York named Impossible Foods chief science officer

David Cortez, PhD, Richard N. Armstrong Professor of Innovation in Biochemistry and professor of biochemistry, has been named interim chair in the Department of Biochemistry beginning Jan. 1, 2021.
By Marissa Shapiro 
July 23, 2020

Cellular antiviral defenses

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
By Leigh MacMillan
1 2 3 4 5 … 16